Aug 13, 2021
- Expanded the total number of research and development programs from 37 to 48 - Announced first internally-developed NCE is advancing to IND-enabling studies - Planning to expand operations to Canada, with Toronto serving as a multidisciplinary hub - Formed Therapeutics Advisory Board chaired by
Jul 12, 2021
Recursion and Bright Horizons partner to open child care center in Gateway Mall, next to Recursion's Salt Lake City headquarters SALT LAKE CITY , July 12, 2021 / PRNewswire / -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological
May 12, 2021
- Strengthened balance sheet with the completion of a successful IPO - Purchased, built, and activated BioHive-1, reportedly the 58th most powerful supercomputer in the world, to accelerate our drug discovery process - Continued development of internal pipeline and partnership programs remain on
Apr 21, 2021
SALT LAKE CITY, April 21, 2021 / PRNewswire / -- Recursion Pharmaceuticals, Inc. ("Recursion" or "we")  announced the closing on April 20, 2021 of its initial public offering of 27,878,787 shares of its Class A common stock, which includes the exercise in full of the underwriters' option to
Displaying 71 - 80 of 98